Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor Inc. (noted as Avalo Therapeutics in metadata, but identified as Cerecor in the filing text) on May 15, 2018. The report details the outcomes of the Company's 2018 Annual Meeting of Stockholders held on that date. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity actions; it does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the Company's most recent 10-K or 10-Q for financial data.
Material Changes and Corporate Actions
- Unregistered Sale of Equity Securities: Following shareholder approval, the Company issued 2,349,968 additional shares of Common Stock. This issuance was contingent on shareholder approval under NASDAQ Listing Rule 5634(d) related to the acquisition of TRx Pharmaceuticals, LLC.
- Equity Incentive Plan: Stockholders approved the Amended and Restated 2016 Equity Incentive Plan, increasing the total number of shares reserved for issuance to 3,915,428 shares.
- Governance Amendments: Stockholders approved amendments to the Certificate of Incorporation and Bylaws to eliminate the classification of the Board of Directors (declassification), allowing for annual elections of all directors.
- Board Elections: Seven nominees were elected to the Board of Directors to serve until the 2019 Annual Meeting.
Shareholder Voting Results and Outcomes
The Annual Meeting included several proposals with mixed results:
- Approved:
- Declassification of the Board (Proposal 1).
- Election of all seven director nominees (Proposal 2).
- Issuance of shares for the TRx Pharmaceuticals acquisition (Proposal 7).
- Amended and Restated 2016 Equity Incentive Plan (Proposal 8).
- Not Approved:
- Elimination of the super-majority vote requirement to amend the Certificate (Proposal 4).
- Elimination of the super-majority vote requirement to amend the Bylaws (Proposal 5).
- Allowance for stockholder action by majority written consent (contingent on Armistice Capital LLC ownership) (Proposal 6).
Investor Verification Checklist
- Verify the impact of the 2,349,968 new shares issued on existing shareholder dilution.
- Review the full text of the Amended and Restated 2016 Equity Incentive Plan (Exhibit 10.1) to understand vesting terms and grant limits.
- Confirm the implications of the failed proposals regarding super-majority voting thresholds and written consent rights on future corporate governance flexibility.
- Check the 2018 Proxy Statement for detailed biographies of the newly elected directors and the rationale behind the failed governance proposals.